MedTrace Logo

RAS and Coagulopathy in COVID19

NCT04419610 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2024-05-03

Study results available
· View outcomes & findings →

Summary

To determine whether the coagulopathy associated with COVID-19 infection is driven by overactivation of the renin angiotensin system (RAS)

Conditions

Interventions

BIOLOGICAL

TRV027

peptide for infusion

OTHER

sodium chloride 0.9%

placebo comparator for infusion

Sponsors & Collaborators

  • Imperial College London

    lead OTHER

Principal Investigators

  • DAVID OWEN · National Health Service, United Kingdom

  • Katrina Pollock · National Health Service, United Kingdom

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-09
Primary Completion
2021-05-12
Completion
2021-05-12
FDA Drug
Yes

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04419610 on ClinicalTrials.gov